Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized …
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
[HTML][HTML] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA …
CARMELINA Investigators - JAMA-JOURNAL OF THE …, 2019 - research.rug.nl
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA …
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - 2019 - observatorio.fm.usp.br
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA …
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - JAMA, 2019 - europepmc.org
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes
and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial …
and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial …
[引用][C] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - JAMA, 2019 - cir.nii.ac.jp
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes
and High Cardiovascular and Renal Risk | CiNii Research CiNii 国立情報学研究所 学術情報 …
and High Cardiovascular and Renal Risk | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML][HTML] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA …
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - JAMA, 2019 - ncbi.nlm.nih.gov
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes
and High Cardiovascular and Renal Risk - PMC Back to Top Skip to main content NIH NLM …
and High Cardiovascular and Renal Risk - PMC Back to Top Skip to main content NIH NLM …
[引用][C] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA …
J Rosenstock, V Perkovic… - JAMA: The Journal …, 2019 - researchportal.helsinki.fi
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes
and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial …
and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA …
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - 2019 - pubmed.ncbi.nlm.nih.gov
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - JAMA, 2019 - elibrary.ru
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …
[引用][C] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA …
J Rosenstock, V Perkovic, OE Johansen, ME Cooper… - 2019 - oparu.uni-ulm.de
0 Http failure response for https://oparu. uni-ulm. de/server/api/core/items/ba130309-4107-
4ba4-869f-4ea7c4d0bf13/bundles? size= 9999&embed= primaryBitstream&embed. size …
4ba4-869f-4ea7c4d0bf13/bundles? size= 9999&embed= primaryBitstream&embed. size …